Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 185

1.

WNT/╬▓-catenin pathway activation correlates with immune exclusion across human cancers.

Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF.

Clin Cancer Res. 2019 Jan 11. pii: clincanres.1942.2018. doi: 10.1158/1078-0432.CCR-18-1942. [Epub ahead of print]

PMID:
30635339
2.

High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.

Blaha DT, Anderson SD, Yoakum DM, Hager MV, Zha Y, Gajewski TF, Kranz DM.

Cancer Immunol Res. 2019 Jan;7(1):50-61. doi: 10.1158/2326-6066.CIR-18-0395. Epub 2018 Nov 13.

PMID:
30425106
3.

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF.

J Clin Oncol. 2018 Sep 28:JCO2018789602. doi: 10.1200/JCO.2018.78.9602. [Epub ahead of print]

4.

Distinct Graft-Specific TCR Avidity Profiles during Acute Rejection and Tolerance.

Miller ML, McIntosh CM, Williams JB, Wang Y, Hollinger MK, Isaad NJ, Moon JJ, Gajewski TF, Chong AS, Alegre ML.

Cell Rep. 2018 Aug 21;24(8):2112-2126. doi: 10.1016/j.celrep.2018.07.067.

5.

Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.

Ishihara J, Ishihara A, Potin L, Hosseinchi P, Fukunaga K, Damo M, Gajewski TF, Swartz MA, Hubbell JA.

Mol Cancer Ther. 2018 Nov;17(11):2399-2411. doi: 10.1158/1535-7163.MCT-18-0091. Epub 2018 Aug 10.

PMID:
30097487
6.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV.

Cell. 2018 Aug 9;174(4):1031-1032. doi: 10.1016/j.cell.2018.07.035. No abstract available.

PMID:
30096300
7.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Carac├▓ C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M.

J Transl Med. 2018 Jul 21;16(1):207. doi: 10.1186/s12967-018-1568-6.

8.

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.

Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF.

J Immunother Cancer. 2018 Jul 16;6(1):73. doi: 10.1186/s40425-018-0384-0.

9.

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR.

Cancer Chemother Pharmacol. 2018 Aug;82(2):309-317. doi: 10.1007/s00280-018-3619-3. Epub 2018 Jun 9.

PMID:
29948021
10.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

11.

Fast Forward - Neoadjuvant Cancer Immunotherapy.

Gajewski TF.

N Engl J Med. 2018 May 24;378(21):2034-2035. doi: 10.1056/NEJMe1803923. No abstract available.

PMID:
29791816
12.

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.

Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R.

J Immunother Cancer. 2018 Apr 4;6(1):24. doi: 10.1186/s40425-018-0334-x.

13.

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.

Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF.

Science. 2018 Mar 23;359(6382):1366-1370. doi: 10.1126/science.aar6918. Review.

PMID:
29567708
14.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.

PMID:
29437535
15.

Back from the dead: TIL apoptosis in cancer immune evasion.

Horton BL, Gajewski TF.

Br J Cancer. 2018 Feb 6;118(3):309-311. doi: 10.1038/bjc.2017.483. Epub 2018 Jan 23. No abstract available.

16.

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.

Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W.

Exp Hematol Oncol. 2018 Jan 11;7:1. doi: 10.1186/s40164-018-0093-x. eCollection 2018.

17.

Impact of oncogenic pathways on evasion of antitumour immune responses.

Spranger S, Gajewski TF.

Nat Rev Cancer. 2018 Mar;18(3):139-147. doi: 10.1038/nrc.2017.117. Epub 2018 Jan 12. Review.

PMID:
29326431
18.

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF.

Science. 2018 Jan 5;359(6371):104-108. doi: 10.1126/science.aao3290.

PMID:
29302014
19.

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S.

Adv Exp Med Biol. 2017;1036:19-31. doi: 10.1007/978-3-319-67577-0_2. Review.

PMID:
29275462
20.

Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.

Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF.

Cancer Immunol Res. 2018 Jan;6(1):14-24. doi: 10.1158/2326-6066.CIR-17-0249. Epub 2017 Nov 2.

Supplemental Content

Loading ...
Support Center